NCT05613153
Peppermint Oil as a Treatment for Children With Bladder and Bowel Dysfunction
Enrolling by Invitation
NAAges 8–17InterventionalTreatmentChildren's Hospital of Orange CountyInvestigator-initiated
~30 participants
Updated 2026-04-08 on ClinicalTrials.gov
What's tested:Peppermint Oil
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Symptom score
Measured over 8 weeks
Conditions
Where it's being run
1 sites across 1 statesCalifornia1
Study leadership
- Heidi A. Stephany, MD · PRINCIPAL_INVESTIGATOR · Children's Hospital, Orange County
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Children aged 8-17 years and weighing 30kg or more with non-neurogenic bladder and bowel dysfunction who have failed behavioral therapy. Behavioral therapy, or also termed standard urotherapy, is defined as encompassing the following components \[15\]: Information and demystification; instruction on avoidance of holding maneuvers, regular bowel habits, proper voiding posture; lifestyle advice encompassing balanced fluid intake and diet, diminished caffeine, regular bladder and bowel emptying patterns; registration of symptoms and voiding habits with bladder diaries or frequency-volume charts; support and encouragement via regular follow up with caregiver. Failure of behavioral therapy is defined as no symptomatology improvement after adherence to behavioral therapy after 6 weeks.
Participants must be able to swallow pills
Exclusion
Patients with neurogenic bladder, tethered cord, Society of Fetal Urology grade 3-4 hydronephrosis, vesicoureteral reflux, learning disabilities, or those who have undergone surgical therapy for bladder and bowel dysfunction will be excluded.
Patients on medical therapy with oxybutynin within the last 30 days.
Patients with hiatal hernia, severe gastrointestinal reflux or gallbladder disorders or on medications for these conditions will be excluded.
Patient weighing less than 30 kg.
What this trial measures
- Symptom score8 weeks
Vancouver Nonneurogenic Lower Urinary Tract Dysfunction/Dysfunctional Elimination Syndrome Questionnaire Score. This includes 13 items scored using a 5-point Likert scale for each item. A score of 0 denotes no complaints and a score of 4 indicates severe symptoms. Range of scores 0-54, with higher scores indicating a worse outcome.